Ibrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis.
In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study
Romeo, Orazio;
2022-01-01
Abstract
Ibrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis.File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
fcimb-12-906563.pdf
accesso aperto
Descrizione: Formato Elettronico
Tipologia:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
468.19 kB
Formato
Adobe PDF
|
468.19 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.